D.E. Shaw & Co’s Adamas Pharmaceuticals ADMS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-293,428
| Closed | -$1.44M | – | 5912 |
|
|
2021
Q3 | $1.44M | Sell |
293,428
-175,432
| -37% | -$852K | ﹤0.01% | 3306 |
|
|
2021
Q2 | $2.48M | Buy |
468,860
+110,968
| +31% | +$574K | ﹤0.01% | 2727 |
|
|
2021
Q1 | $1.72M | Sell |
357,892
-318,234
| -47% | -$1.66M | ﹤0.01% | 2715 |
|
|
2020
Q4 | $2.93M | Buy |
676,126
+82,179
| +14% | +$352K | ﹤0.01% | 2293 |
|
|
2020
Q3 | $2.45M | Buy |
593,947
+409,847
| +223% | +$1.59M | ﹤0.01% | 2246 |
|
|
2020
Q2 | $471K | Buy |
184,100
+106,517
| +137% | +$313K | ﹤0.01% | 3404 |
|
|
2020
Q1 | $224K | Buy |
+77,583
| New | +$348K | ﹤0.01% | 3599 |
|
|
2019
Q4 | – | Sell |
-71,724
| Closed | -$367K | – | 4250 |
|
|
2019
Q3 | $367K | Buy |
+71,724
| New | +$443K | ﹤0.01% | 3355 |
|
|
2017
Q4 | – | Sell |
-22,526
| Closed | -$477K | – | 3805 |
|
|
2017
Q3 | $477K | Buy |
+22,526
| New | +$413K | ﹤0.01% | 2935 |
|
|
2016
Q1 | – | Sell |
-34,474
| Closed | -$976K | – | 3889 |
|
|
2015
Q4 | $976K | Buy |
34,474
+16,538
| +92% | +$278K | ﹤0.01% | 2644 |
|
|
2015
Q3 | $300K | Buy |
+17,936
| New | +$408K | ﹤0.01% | 3346 |
|
|
2014
Q4 | – | Sell |
-12,969
| Closed | -$241K | – | 4345 |
|
|
2014
Q3 | $241K | Sell |
12,969
-20,415
| -61% | -$351K | ﹤0.01% | 3801 |
|
|
2014
Q2 | $610K | Buy |
+33,384
| New | +$598K | ﹤0.01% | 3366 |
|
D.E. Shaw & Co's ADMS Position: Q4 2021 in Review
D.E. Shaw & Co sold out of Adamas Pharmaceuticals (ADMS) in Q4 2021, closing a stake of 293,428 shares — an estimated $1.44M sold.
D.E. Shaw & Co first reported a position in ADMS in Q2 2014 and held it in 13 quarters. The position peaked at $2.93M in Q4 2020. 0 funds tracked by Wall St. Rank hold ADMS as of Q4 2021.
- D.E. Shaw & Co reported no remaining Adamas Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
- D.E. Shaw & Co sold 293,428 Adamas Pharmaceuticals shares in Q4 2021, an estimated $1.44M.
- D.E. Shaw & Co first reported a position in Adamas Pharmaceuticals in Q2 2014 and held it in 13 quarters.
- D.E. Shaw & Co's Adamas Pharmaceuticals position peaked at $2.93M in Q4 2020.
- 0 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2021.
Based on D.E. Shaw & Co's 13F filing for Q4 2021, filed 14 Feb 2022.